AbGenomics

AbGenomics is focused on developing targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases.

AbGenomics International Inc., incorporated in Delaware with principal office in SFO Bay Area California, is a biopharmaceutical company integrated globally and virtually to develop targeted antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. With its R&D foundation in Taipei Taiwan since June 2000, AbGenomics has been focusing on the discovery and development of novel therapeutics for the unmet medical needs. Our R&D scientists built an efficient discovery platform to identify and validate novel antibody therapeutics. Currently, AbGenomics has several potential therapeutic antibodies targeting against autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, and other solid tumors in various development stages. To increase the efficacy and success rates, companion diagnostic methods specific for those therapeutics are also being developed. We intend to build a diversified product portfolio through our R&D and partnerships